Moderna PE Ratio 2017-2021 | MRNA

Current and historical p/e ratio for Moderna (MRNA) from 2017 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Moderna PE ratio as of December 07, 2021 is 17.31.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Moderna PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-12-06 265.33 16.27
2021-09-30 384.86 $16.31 23.60
2021-06-30 234.98 $8.02 29.30
2021-03-31 130.95 $1.25 104.76
2020-12-31 104.47 $-1.94 0.00
2020-09-30 70.75 $-1.62 0.00
2020-06-30 64.21 $-1.40 0.00
2020-03-31 29.95 $-1.50 0.00
2019-12-31 19.56 $-1.55 0.00
2019-09-30 15.92 $-1.18 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $114.479B $0.803B
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71